Sequana Medical Announces Granting of Key alfapump DSR® Patents in U.S. and Europe


GHENT, Belgium, Feb. 04, 2021 (GLOBE NEWSWIRE) -- Sequana Medical NV (Euronext Brussels: SEQUA), an innovator in the treatment of diuretic-resistant fluid overload in liver disease, malignant ascites and heart failure, today announces the granting of key patents for the alfapump DSR (Direct Sodium Removal) programme in the U.S. and European Union.

Read the original:
Sequana Medical Announces Granting of Key alfapump DSR® Patents in U.S. and Europe

Related Posts